Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Transitional Cell 15Neoplasms 14Ovarian Neoplasms 13Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Carcinoma, Merkel Cell 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Melanoma 7Stomach Neoplasms 6Recurrence 5Breast Neoplasms 5Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Lymphoma, Non-Hodgkin 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Urothelial Cancer 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × avelumab × Clear all
NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

NKGen Biotech, Inc.

Phase 1 Completed
27 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

EMD Serono

Phase 3 Completed
371 enrolled 18 charts
Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02603419 2020-04-24

JAVELIN HODGKINS

Pfizer

Phase 1 Terminated
34 enrolled 43 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡